24/7 Market News Snapshot 11 September, 2025 – Silexion Therapeutics Corp Ordinary Shares (NASDAQ:SLXN)

September 11, 2025

DENVER, Colo., 11 September, 2025 (www.247marketnews.com) – (NASDAQ:SLXN) are discussed in this article.
Silexion Therapeutics Corp. (NASDAQ:SLXN) has garnered significant attention in the financial markets, currently trading at $23.24, reflecting an extraordinary increase of 418.1% from its previous close of $4.49. This surge has captured investor confidence, showcasing a robust trading volume of 2.02 million shares, which indicates heightened market interest and potential for a breakout. Analysts attribute this momentum to the company’s recent advancements in groundbreaking RNA interference (RNAi) therapies, particularly its lead candidate, SIL204, poised to become a pivotal treatment for KRAS-driven pancreatic cancer.

The latest preclinical studies reveal promising results for SIL204, demonstrating effective targeting of pancreatic cancer metastases through subcutaneous administration. Target organs, including the liver, peritoneum, and lung, are more accessible as a result. Significantly, over 80% of deaths from pancreatic cancer can be associated with metastatic disease, underscoring the importance of these findings. The research indicates a substantial reduction in tumor burden at multiple sites after administration, reinforcing the efficacy of SIL204 as a possible systemic therapy.

Dr. Mitchell Shirvan, Chief Scientific Officer, highlighted the innovative dual-route administration strategy that enables SIL204 to distribute effectively to major metastatic sites, resulting in notable tumor reductions within just a week of treatment. Meanwhile, Ilan Hadar, Chairman and CEO, emphasized the implications of these results in addressing a critical challenge in pancreatic cancer management—reaching micrometastases.

Looking ahead, Silexion aims to initiate Phase 2/3 clinical trials in the first half of 2026, with regulatory submissions anticipated for late 2025 and early 2026. Furthermore, the company is committed to expanding research on SIL204’s applicability against various cancer types and KRAS mutations, with additional results forthcoming. Silexion maintains a steadfast dedication to innovating treatment options for solid tumors driven by the mutated KRAS oncogene, setting the stage for transformative advancements in pancreatic cancer therapy.

Related news for (SLXN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.